

FORM 1449*

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Docket Number:

11669.0113USC1

Application Number:

10/648,816


IN AN APPLICATION

(Use several sheets if necessary)

Applicant: Van Bruggen et al.

Filing Date: August 26, 2003

Group Art Unit: 1643



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ALH	U.S. 4,456,550	06/26/84	Dvorak et al.	260	112 R	11/22/82
ALH	U.S. 5,518,999	05/21/96	Nakamura et al.	514	8	11/09/94

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
ALH	WO 97/49408	12/31/97	WIPO				
ALH	WO 98/48795	11/05/98	WIPO				
ALH	WO 00/27414	05/18/00	WIPO				
ALH	WO 00/29584	05/25/00	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ALH		Copy of European Search Report dated August 4, 2005

23552

PATENT TRADEMARK OFFICE

EXAMINER

/Anne Holleran/ (06/25/2006)

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Amy Docket No.

P1717D1

Serial No.

09/718694

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant


VAN BRUGGEN

Filing Date

21 Nov 2000

Group	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
1	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	• 1	5,306,710	26.04.94	Wei, E.			
	• 2	5,955,311	21.09.99	Rockwell et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
ALH ↓	* 3	WO 94/10202	11.05.94	PCT				
	* 4	WO 97/44453	27.11.97	PCT				
	* 5	WO 98/16551	23.04.98	PCT				
	* 6	WO 98/45331	15.10.98	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

7	Berkman et al., "Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms" <u>J. Clin. Invest.</u> 91(1):153-159 (1993)	<i>duplicate cit.</i>
8	Risau, W., "Molecular biology of blood-brain barrier ontogenesis and function" <u>Acta Neurochirurgica</u> (abstract only) 60:109-112 (1994)	
9	<u>Taber's Cyclopedic Medical Dictionary</u> , 16th edition, Philadelphia:F.A. Davis Company pps. 742 (1989)	
10	van Bruggen et al., "VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain" <u>Journal of Clinical Investigation</u> 104(11):1613-1620 (Dec 1999)	<i>duplicate citation</i>

Examiner

/Anne Holleran/ (06/25/2006)

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.113USDI	Application Number: 09/718,694
	Applicant: van Bruggen et al.	
	Filing Date: 11/21/2000	Group Art Unit: 1642

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
ALH	Berkman, R. et al., "Expression of the Vascular Permeability Factor/Vascular Endothelial Growth Factor Gene in Central Nervous System Neoplasms", <i>The Journal of Clinical Investigation, Inc.</i> , 91:153-159 (January 1993)					
	Hayashi, T. et al., "Reduction of Ischemic Damage by Application of Vascular Endothelial Growth Factor in Rat Brain After Transient Ischemia", <i>Journal of Cerebral Blood Flow and Metabolism</i> , 18:887-895 (1998)					
	Kalkanis, S. et al., "Correlation of vascular endothelial growth factor messenger RNA expression with peritumoral vasogenic cerebral edema in meningiomas", <i>J. Neurosurg.</i> , 85:1095-1101 (1996)					
	Vaquero, J. et al., "Expression of vascular permeability factor in glioblastoma specimens: correlation with tumor vascular endothelial surface and peritumoral edema", <i>Journal of Neuro-Oncology</i> , 49:49-55 (2000)					
	Van Bruggen, N. et al., "VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain", <i>The Journal of Clinical Investigation</i> , 104(11):1613-1620 (December 1999)					
	Gossmann, A. et al., "Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Marker of Tumor Response to Anti-Angiogenic Therapy in a Xenograft Model of Glioblastoma Multiforme", <i>Journal of Magnetic Resonance Imaging</i> , 15:233-240 (2002)					
	Ferrara, N. et al., "Vascular endothelial growth factor is essential for corpus luteum angiogenesis", <i>Nature Medicine</i> , 4(3) 336-340 (March 1998)					
↓	Strugar, J. et al., "Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis", <i>J. Neurosurg.</i> , 81:560-566 (October 1994)					



EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	